Table 2.
Studies Using Chemotherapeutic Agents in Relapsed Osteosarcoma
| Author | Year of Publication | Phase | Number | Regimen | ORR % | CR/PR (Number) |
|---|---|---|---|---|---|---|
| Harris et al99 | 1995 | II | 30 | Ifosfamide | 30 | 1/2 |
| Kung et al183 | 1993 | II | 32 | Ifosfamide + Etoposide | 15 | 2/3 |
| Miser et al184 | 1987 | II | 8 | Ifosfamide + Etoposide | 37 | 0/3 |
| Cairo et al185 | 2001 | II | 23 | Ifosfamide + Etoposide + Carboplatin | 30 | NA |
| Berrak et al186 | 2005 | R | 16 | High dose Ifosfamide | 62 | 6/4 |
| Gentet et al100 | 1997 | II | 27 | High dose Ifosfamide + Etoposide | 48 | 6/7 |
| Lee et al101 | 2016 | R | 28 | Gemcitabine + Docetaxel | 14 | 1/1 |
| Navid et al187 | 2008 | R | 17 | Gemcitabine + Docetaxel | 17 | 0/3 |
| Qi et al188 | 2012 | R | 18 | Gemcitabine + Docetaxel | 5 | 0/1 |
| Palmerini et al189 | 2016 | R | 40 | Gemcitabine + Docetaxel | 17 | 0/6 |
| Fox et al102 | 2012 | II | 14 | Gemcitabine + Docetaxel | 5 | 0/1 |
| Berger et al103 | 2009 | II | 26 | Cyclophosphamide + Etoposide | 19 | 0/5 |
| Rodriguez-Galindo et al104 | 2002 | II | 14 | Cyclophosphamide + Etoposide | 28 | 1/3 |
| Grignani et al105 | 2012 | II | 35 | Sorafenib | 8 | 0/3 |
| Grignani et al106 | 2015 | II | 38 | Sorafenib + Everolimus | 5 | 0/2 |
| Duffaud et al107 | 2019 | II | 43 | Regorafenib | 8 | 0/2 |
| Davis et al108 | 2019 | II | 42 | Regorafenib | 13 | 0/3 |
Abbreviations: CR, complete remission; ORR, overall response rate; PR, partial remission; R, retrospective.